$PALI
PALISADE BIO, INC.

2023 Q2 Form 10-Q Financial Statement

#000095017023021374 Filed on May 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q4
Revenue $0.00 $250.0K $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.432M $1.538M $1.505M
YoY Change -36.5% -47.49% -53.36%
% of Gross Profit
Research & Development $2.177M $1.241M $2.343M
YoY Change 65.3% 29.41% 192.88%
% of Gross Profit
Depreciation & Amortization $2.000K $1.000K $2.000K
YoY Change 0.0%
% of Gross Profit
Operating Expenses $3.609M $2.779M $3.848M
YoY Change 1.04% -28.52% -4.44%
Operating Profit -$3.609M -$2.529M
YoY Change 1.04% -34.95%
Interest Expense $3.000K $0.00 $20.00K
YoY Change -40.0% -100.0% -99.61%
% of Operating Profit
Other Income/Expense, Net $216.0K $189.0K $108.0K
YoY Change -82.41% -159.62% 881.82%
Pretax Income -$3.393M -$2.340M -$3.720M
YoY Change 44.75% -44.35% -446.69%
Income Tax
% Of Pretax Income
Net Earnings -$3.393M -$2.340M -$3.720M
YoY Change 44.75% -44.35% -446.69%
Net Earnings / Revenue -936.0%
Basic Earnings Per Share -$0.53 -$0.54
Diluted Earnings Per Share -$0.53 -$0.54 -$2.06
COMMON SHARES
Basic Shares Outstanding 6.697M 4.504M 77.08M
Diluted Shares Outstanding 6.418M 4.316M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.40M $13.30M $12.38M
YoY Change 229.38% 100.14% 17.99%
Cash & Equivalents $16.40M $13.30M $12.40M
Short-Term Investments
Other Short-Term Assets $973.0K $684.0K $912.0K
YoY Change -59.71% -55.24% -51.46%
Inventory
Prepaid Expenses
Receivables $300.0K $0.00
Other Receivables $78.00K
Total Short-Term Assets $17.41M $14.31M $14.73M
YoY Change 134.81% 73.27% 19.06%
LONG-TERM ASSETS
Property, Plant & Equipment $11.00K $9.000K $10.00K
YoY Change 450.0% 350.0% 233.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $592.0K $643.0K $694.0K
YoY Change 2176.92% 2373.08% 2569.23%
Total Long-Term Assets $879.0K $953.0K $1.030M
YoY Change 124.81% 935.87% 646.38%
TOTAL ASSETS
Total Short-Term Assets $17.41M $14.31M $14.73M
Total Long-Term Assets $879.0K $953.0K $1.030M
Total Assets $18.29M $15.26M $15.76M
YoY Change 134.31% 82.78% 25.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $922.0K $706.0K $1.759M
YoY Change -11.43% -38.45% 32.96%
Accrued Expenses $598.0K $309.0K $574.0K
YoY Change -42.17% -46.72% 23.97%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $411.0K $0.00 $88.00K
YoY Change -32.73% 1.15%
Total Short-Term Liabilities $2.335M $1.315M $3.012M
YoY Change -18.36% -29.45% 20.67%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $155.0K $200.0K $272.0K
YoY Change -78.91% -88.19% -89.74%
Total Long-Term Liabilities $155.0K $200.0K $272.0K
YoY Change -78.91% -88.19%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.335M $1.315M $3.012M
Total Long-Term Liabilities $155.0K $200.0K $272.0K
Total Liabilities $2.490M $1.515M $3.284M
YoY Change -30.74% -57.42% -36.2%
SHAREHOLDERS EQUITY
Retained Earnings $114.9M $111.5M $109.2M
YoY Change 13.54% 12.85% 15.43%
Common Stock $69.00K $46.00K $30.00K
YoY Change -68.64% -74.86% -79.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $15.80M $13.75M $12.48M
YoY Change
Total Liabilities & Shareholders Equity $18.29M $15.26M $15.76M
YoY Change 134.31% 82.78% 25.98%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q4
OPERATING ACTIVITIES
Net Income -$3.393M -$2.340M -$3.720M
YoY Change 44.75% -44.35% -446.69%
Depreciation, Depletion And Amortization $2.000K $1.000K $2.000K
YoY Change 0.0%
Cash From Operating Activities -$2.199M -$3.526M -$3.306M
YoY Change -32.34% -6.32% 8.22%
INVESTING ACTIVITIES
Capital Expenditures $4.000K $10.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$4.000K -$10.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.309M 4.440M 1.714M
YoY Change 234.74% -5203.45% -409.39%
NET CHANGE
Cash From Operating Activities -2.199M -3.526M -3.306M
Cash From Investing Activities -4.000K -10.00K
Cash From Financing Activities 5.309M 4.440M 1.714M
Net Change In Cash 3.106M 914.0K -1.602M
YoY Change -286.66% -123.73% -55.61%
FREE CASH FLOW
Cash From Operating Activities -$2.199M -$3.526M -$3.306M
Capital Expenditures $4.000K $10.00K
Free Cash Flow -$2.203M -$3.316M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001357459
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-33672
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
PALISADE BIO, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
52-2007292
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
7750 El Camino Real, Suite 2A
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Carlsbad
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92009
CY2023Q1 dei City Area Code
CityAreaCode
858
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
704-4900
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value
CY2023Q1 dei Trading Symbol
TradingSymbol
PALI
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6696982
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13297000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12383000
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
250000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
762000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2350000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
14309000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
14733000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
275000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
300000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
643000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
694000
CY2023Q1 us-gaap Assets
Assets
15262000
CY2022Q4 us-gaap Assets
Assets
15763000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
706000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1759000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
309000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
574000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
191000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
486000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
109000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
105000
CY2023Q1 pali Long Term Debt Current Maturities Excluding Related Party Debt
LongTermDebtCurrentMaturitiesExcludingRelatedPartyDebt
0
CY2022Q4 pali Long Term Debt Current Maturities Excluding Related Party Debt
LongTermDebtCurrentMaturitiesExcludingRelatedPartyDebt
88000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1315000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3012000
CY2023Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
18000
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
61000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
182000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
211000
CY2023Q1 us-gaap Liabilities
Liabilities
1515000
CY2022Q4 us-gaap Liabilities
Liabilities
3284000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
280000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
280000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4563977
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4563977
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2944306
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2944306
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
46000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
30000
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
125229000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
121637000
CY2023Q1 pali Retained Earnings Accumulated Income Deficit
RetainedEarningsAccumulatedIncomeDeficit
-111530000
CY2022Q4 pali Retained Earnings Accumulated Income Deficit
RetainedEarningsAccumulatedIncomeDeficit
-109190000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
13747000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
12479000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15262000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15763000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
250000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2023Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1241000
CY2022Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
959000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1538000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2929000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
2779000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
3888000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2529000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3888000
CY2023Q1 us-gaap Interest Expense
InterestExpense
0
CY2022Q1 us-gaap Interest Expense
InterestExpense
1000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
189000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
794000
CY2023Q1 pali Financing Cost Derivative Warrant Liabilities
FinancingCostDerivativeWarrantLiabilities
0
CY2022Q1 pali Financing Cost Derivative Warrant Liabilities
FinancingCostDerivativeWarrantLiabilities
1110000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
189000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-317000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2340000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-4205000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-12.96
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-12.96
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4315526
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4315526
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
324473
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
324473
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
12479000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2340000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
93000
CY2023Q1 pali Stock Issued During Period Value Of Common Stock Upon Warrant Exercises
StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises
1349000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2166000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
13747000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
7365000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-4205000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
358000
CY2022Q1 pali Stock Issued During Period Value Of Common Stock Upon Warrant Exercises
StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises
1274000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
4792000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2340000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-4205000
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1000
CY2023Q1 pali Noncash Lease Expense
NoncashLeaseExpense
25000
CY2022Q1 pali Noncash Lease Expense
NoncashLeaseExpense
45000
CY2023Q1 pali Issuance Cost Allocated To Warrants
IssuanceCostAllocatedToWarrants
0
CY2022Q1 pali Issuance Cost Allocated To Warrants
IssuanceCostAllocatedToWarrants
1110000
CY2023Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
43000
CY2022Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
793000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
93000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
358000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
250000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-278000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-265000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-970000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-59000
CY2023Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-295000
CY2022Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-439000
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-25000
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-47000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3526000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3764000
CY2023Q1 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
88000
CY2022Q1 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
87000
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2231000
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2023Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2710000
CY2022Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
CY2023Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
413000
CY2022Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4440000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-87000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
914000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3851000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12409000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10521000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13323000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6670000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13297000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6644000
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
26000
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
26000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13323000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6670000
CY2023Q1 pali Equity Issuance Costs Included In Accounts Payable
EquityIssuanceCostsIncludedInAccountsPayable
12000
CY2022Q1 pali Equity Issuance Costs Included In Accounts Payable
EquityIssuanceCostsIncludedInAccountsPayable
82000
CY2023Q1 pali Issuance Of Common Stock For Cashless Exercise Of Warrants
IssuanceOfCommonStockForCashlessExerciseOfWarrants
0
CY2022Q1 pali Issuance Of Common Stock For Cashless Exercise Of Warrants
IssuanceOfCommonStockForCashlessExerciseOfWarrants
1274000
CY2023Q1 pali Fair Value Of Warrants Issued To Placement Agent
FairValueOfWarrantsIssuedToPlacementAgent
173000
CY2022Q1 pali Fair Value Of Warrants Issued To Placement Agent
FairValueOfWarrantsIssuedToPlacementAgent
0
CY2023Q1 pali Cash Receivable For Exercises Of Warrants Included In Prepaid And Other Assets And Other Noncurrent Assets
CashReceivableForExercisesOfWarrantsIncludedInPrepaidAndOtherAssetsAndOtherNoncurrentAssets
48000
CY2022Q1 pali Cash Receivable For Exercises Of Warrants Included In Prepaid And Other Assets And Other Noncurrent Assets
CashReceivableForExercisesOfWarrantsIncludedInPrepaidAndOtherAssetsAndOtherNoncurrentAssets
0
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
111500000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13300000
CY2023Q1 us-gaap Deferred Costs Current
DeferredCostsCurrent
93000
CY2022Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
114000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-4205000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4315526
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates, judgments, and assumptions that impact the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the balance sheet, and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s condensed consolidated financial statements relate to clinical trial accruals and its derivative financial instruments. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.</span></p>
CY2023Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents and accounts receivable. The Company maintains deposits in federally insured financial institutions and in money market accounts, and at times balances may exceed federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held nor has the Company experienced any losses in these accounts. The Company's entire accounts receivable balance as of March 31, 2023 is with the Company co-development partner, Newsoara Biopharma Co., Ltd. (“Newsoara”) (See Note 8, Collaborations and License Agreements). Management believes it is not exposed to significant credit risk on the accounts receivable based on its relationship with Newsoara and Newsoara's history of timely payment of balances owed. In early May 2023, prior to the issuance of these condensed consolidated financial statements, Newsoara has paid the entire balance of the accounts receivable outstanding as of March 31, 2023</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
CY2023Q1 us-gaap Revenue Recognition Software
RevenueRecognitionSoftware
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Milestone Revenue</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company uses the revenue recognition guidance established by ASC 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue From Contracts With Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (“ASC 606”). When an agreement falls under the scope of other standards, such as ASC 808, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaborative Arrangements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. The Company currently does not have any collaborative arrangements with counterparties that are also considered customers. For arrangements that include amounts to be paid to the Company upon the achievement of certain development milestones of technology licensed by the Company, the Company recognizes such license revenue using the most likely method. At the end of each reporting period, the Company re-evaluates the probability or achievement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of any potential milestones and any related constraints, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue in the period of adjustment. For the three months ended March 31, 2023</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of license revenue related to milestones achieved on licensed technology </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">was recognized as revenue and was reported in accounts receivable as of March 31, 2023, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to which the Company has not recorded an allowance for estimated credit losses based on its relationship with the counterparty and the counterparty's history of timely payment of balances owed to the Company (see Note 8, Collaborations and License Agreements).</span></p>
CY2023Q1 pali Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
94000
CY2022Q4 pali Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
184000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2340000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
324473
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-12.96
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2340000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-4205000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4315526
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
324473
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-12.96
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1710492
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
138015
CY2023Q1 us-gaap Prepaid Insurance
PrepaidInsurance
355000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
581000
CY2023Q1 pali Prepaid Expenses And Other Current Assets Other Receivables
PrepaidExpensesAndOtherCurrentAssetsOtherReceivables
78000
CY2022Q4 pali Prepaid Expenses And Other Current Assets Other Receivables
PrepaidExpensesAndOtherCurrentAssetsOtherReceivables
1438000
CY2023Q1 pali Prepaid Subscriptions And Fees
PrepaidSubscriptionsAndFees
193000
CY2022Q4 pali Prepaid Subscriptions And Fees
PrepaidSubscriptionsAndFees
157000
CY2023Q1 pali Prepaid Software Licenses
PrepaidSoftwareLicenses
37000
CY2022Q4 pali Prepaid Software Licenses
PrepaidSoftwareLicenses
54000
CY2023Q1 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
93000
CY2022Q4 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
114000
CY2023Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
6000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
6000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
762000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2350000
CY2023Q1 pali Cash Receivable For Exercises Of Warrants Included In Prepaid And Other Assets And Other Noncurrent Assets
CashReceivableForExercisesOfWarrantsIncludedInPrepaidAndOtherAssetsAndOtherNoncurrentAssets
47600
CY2022 pali Cash Receivable For Exercises Of Warrants Included In Prepaid And Other Assets And Other Noncurrent Assets
CashReceivableForExercisesOfWarrantsIncludedInPrepaidAndOtherAssetsAndOtherNoncurrentAssets
1400000
CY2023Q1 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
631000
CY2022Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
682000
CY2023Q1 pali Other Noncurrent Assets
OtherNoncurrentAssets
12000
CY2022Q4 pali Other Noncurrent Assets
OtherNoncurrentAssets
12000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
643000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
694000
CY2023Q1 pali Accrued Accounts Payable
AccruedAccountsPayable
73000
CY2022Q4 pali Accrued Accounts Payable
AccruedAccountsPayable
69000
CY2023Q1 pali Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
94000
CY2022Q4 pali Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
184000
CY2023Q1 pali Accrued Director Stipends
AccruedDirectorStipends
108000
CY2022Q4 pali Accrued Director Stipends
AccruedDirectorStipends
141000
CY2023Q1 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
5000
CY2022Q4 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
180000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
29000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
309000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
574000
CY2023Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1604421
CY2022Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1055672
CY2022Q4 pali Class Of Warrant Or Right Number Outstanding
ClassOfWarrantOrRightNumberOutstanding
1055672
CY2022 pali Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
26.48
CY2022 pali Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife
P3Y3M25D
CY2023Q1 pali Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
1691578
CY2023Q1 pali Class Of Warrant Or Right Issued During Period Weighted Average Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice
1.59
CY2023Q1 pali Class Of Warrant Or Right Issued During Period Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageRemainingContractualLife
P4Y9M3D
CY2023Q1 pali Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
1142829
CY2023Q1 pali Class Of Warrant Or Right Exercised During Period Weighted Average Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice
1.18
CY2023Q1 pali Class Of Warrant Or Right Exercised During Period Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageRemainingContractualLife
P1Y4M24D
CY2023Q1 pali Class Of Warrant Or Right Number Outstanding
ClassOfWarrantOrRightNumberOutstanding
1604421
CY2023Q1 pali Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
18.26
CY2023Q1 pali Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife
P4Y4M28D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
63789
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
174.70
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
280000000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.36
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
48.67
CY2023Q1 pali Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm
P5Y9M21D
CY2022Q1 pali Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm
P5Y9M21D
CY2023Q1 pali Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate
0.0376
CY2022Q1 pali Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate
0.0185
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.6954
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.7377
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
43658
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
311.74
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y29D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
30620
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.36
CY2023Q1 pali Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractualterm2
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualterm2
P9Y10M17D
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
10489
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
242.03
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M12D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
35644000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
63789
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
174.70
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y8M12D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
35644000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
22383
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
463.61
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y11M19D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.51
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
100000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
93000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
358000
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
500000
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y10M2D
CY2018 pali Collaborations And License Agreements Upfront Fee
CollaborationsAndLicenseAgreementsUpfrontFee
1000000.0
CY2018 us-gaap Royalty Expense
RoyaltyExpense
6750000
CY2023Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
300000
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
300000
CY2022Q1 pali Milestone Payments
MilestonePayments
0
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
100000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
136000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
93000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
329000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
38000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
291000
CY2021Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
7549
CY2021Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
172.50
CY2023Q1 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2026-08-26
CY2023Q1 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
107500
CY2022Q4 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
141250

Files In Submission

Name View Source Status
0000950170-23-021374-index-headers.html Edgar Link pending
0000950170-23-021374-index.html Edgar Link pending
0000950170-23-021374.txt Edgar Link pending
0000950170-23-021374-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
pali-20230331.htm Edgar Link pending
pali-20230331.xsd Edgar Link pending
pali-ex31_1.htm Edgar Link pending
pali-ex31_2.htm Edgar Link pending
pali-ex32_1.htm Edgar Link pending
R1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
pali-20230331_cal.xml Edgar Link unprocessable
pali-20230331_lab.xml Edgar Link unprocessable
pali-20230331_def.xml Edgar Link unprocessable
pali-20230331_pre.xml Edgar Link unprocessable
pali-20230331_htm.xml Edgar Link completed
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending